LifeSci Capital analyst Cory Jubinville downgraded CymaBay (CBAY) to Market Perform from Outperform with a $32.50 price target after Gilead Sciences (GILD) announced an agreement to acquire Cymabay for $32.50 per share in cash.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- CymaBay downgraded to Market Perform from Strong Buy at Raymond James
- CymaBay downgraded to Neutral from Buy at B. Riley
- CymaBay downgraded to Neutral from Overweight at Cantor Fitzgerald
- CymaBay downgraded to Hold from Buy at JonesResearch
- Gilead acquisition of CymaBay makes sense, says Wells Fargo
